

Amended

- 94. The method of claim 92, wherein the molecule of interest is an immunoglobulin molecule.
- 95. The method of claim 92, wherein the molecule of interest is an enzyme.
- 96. The method of claim 68, wherein said method is for identifying a molecule of interest, further comprising the step of:
 - biopanning to identify the molecule of interest.
- 97. The method of claim 79, wherein said method is for identifying a molecule of interest, further comprising the step of:
 - biopanning to identify the molecule of interest. --

REMARKS

Claims 1-56 are canceled herein without prejudice. Claims 57-97 are added herein to more particularly define the invention. Support for new claim 57 can be found in claims 43 and 51 as originally filed and in the specification on page 3, lines 6-9, and page 12, lines 11-13. Support for claims 58-61 can be found on page 9, lines 27-28, page 10, line 1, and page 11, lines 13-21. Support for claim 62 can be found on page 2, lines 19-22. Support for claim 63 can be found on page 2, lines 15-16, page 7, lines 22-23 and page 12, lines 11-13. Support for claims 64-65 can be found in claims 46 and 47 as originally filed. Support for claim 66 can be found in claim 4 as originally filed. Support for claim 67 can be found on page 12, lines 1-2. Support for claim 68 can be found in claim 1 as originally filed. Support for claims 69-72 can be found on page 9, lines 27-28, page 10, line 1, and page 11, lines 13-21. Support for claim 73 can be found on page 2, lines 19-22. Support for claim 74 can be found on page 2, lines 15-16, page 7, lines 22-23 and page 12, lines 11-13. Support for claims 75 and 76 can be found in claims 18 and 19

as filed. Support for claim 77 can be found in claim 4 as originally filed. Support for claim 78 can be found on page 12, lines 1-2. Support for claim 79 can be found in claim 22 as originally filed. Support for claims 80-83 can be found on page 9, lines 27-28, page 10, line 1, and page 11, lines 13-21. Support for claim 84 can be found on page 2, lines 15-16. Support for claim 85 can be found on page 2, lines 15-16, page 7, lines 22-23 and page 12, lines 11-13. Support for claims 86 and 87 can be found in claims 40 and 41 as filed. Support for claim 88 can be found on page 12, lines 1-2. Support for claim 90-91 can be found in claim 42 as originally filed. Support for claims 92 -95 can be found on page 11, lines 13-21. Support for claims 96 and 97 can be found on pages 36-38 of the specification. Support for claims 57-97 can also be found elsewhere throughout the specification. Applicants believe that no new matter is being introduced by these new claims, and applicants respectfully request that the new claims be entered.

The Examiner has restricted the invention into six groups:

Group I:	Claims 1-21, Group I, drawn to a method of displaying a polypeptide on a surface lattice protein.
Group II:	Claims 22-36, drawn to a method of displaying a polypeptide on the surface of a virion.
Group III:	Claims 37-42, drawn to a method of immunizing a mammal with an antigenic composition.
Group IV:	Claims 43-47, drawn to a therapeutic composition.
Group V:	Claims 51-55, drawn to a chimeric polypeptide that binds to a surface lattice protein and a protein of interest.

Group VI: Claims 48-50 and 56, drawn to an encoding nucleic acid molecule.

New claim 57 is an independent claim which recites a composition containing a T4 surface lattice protein array and a chimera comprising a molecule of interest, a T4 dispensable polypeptide and a linker, wherein the linker links the molecule of interest to the T4 dispensable polypeptide and wherein said chimera is bound to the T4 surface lattice protein array. New claims 58-97 all depend either directly or indirectly from claim 57 such that all claims now depend from claim 57 in Group IV.

Applicants provisionally elect Group IV, new claims 57-97, with traverse. Applicants also request that the restriction requirement be reconsidered because the Examiner has not shown that a serious burden would be required to examine all of the claims. M.P.E.P. § 803 provides:

If the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it includes claims to distinct or independent inventions. (*Emphasis added.*)

Thus, for a restriction requirement to be proper, the Examiner must satisfy the following two criteria: (1) the existence of independent and distinct inventions (35 U.S.C. § 121); and (2) that the search and examination of the entire application cannot be made without serious burden.

Applicants respectfully assert that the Examiner has not shown that the second requirement has been met on the basis that the Examiner has not shown that it would be a serious burden to search and examine all of the claims together. Applicants have canceled claims 1-56 herein and added new claims 57-97 such that the subject matter of the claims in Groups I, II, III and V is now recited in claims that depend from claim 57 in elected Group IV. Therefore, if

claim 57, the broadest claim, is found to be free of the prior art, any claim depending from claim 57 should also be free of the prior art. Thus, this criterion of M.P.E.P. § 803 as set forth above has not been satisfied, because the Examiner has not shown that it would be a serious burden to search and examine all of the claims of this invention together.

For the reasons stated above, applicants respectfully assert that restriction of the claims as set forth by the Examiner would be contrary to promoting efficiency, economy and expediency in the U.S. Patent and Trademark Office and further point out that restriction by the Examiner is discretionary (M.P.E.P. § 803.01). Thus, applicants respectfully request that all of the claims of this application be examined together. Consequently, reconsideration and modification or withdrawal of the restriction requirement is requested.

Applicants also wish to remind the Examiner of the guidelines for rejoinder of claims as set forth in M.P.E.P. § 821.04, as they apply to the pending claims of the instant application.

A check in the amount of \$1,850.00 and a Request for a Five Month Extension of Time are enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to

DOCKET NO. 14014.0327
Serial No. 08/837,301

Deposit Account No. 14-0629.

Respectfully submitted,

Mary L. Miller
Mary L. Miller
Registration No. 39,303

Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
(404) 688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 1, 2000.

Mary L. Miller
Mary L. Miller

May 1, 2000
Date